| Literature DB >> 31194087 |
Luanluan Jia1,2, Fengxuan Han1,2, Huan Wang1, Caihong Zhu2, Qianping Guo2, Jiaying Li2, Zhongliang Zhao2, Qiang Zhang3, Xuesong Zhu1, Bin Li1,2,4.
Abstract
Along with the massive use of implants in orthopaedic surgeries in recent few decades, there has been a tremendous demand for the surface modification of the implants to avoid surgery failure and improve their function. Polydopamine (PDA), being able to adhere to almost all kinds of substrates and possessing copious functional groups for covalently immobilizing biomolecules and anchoring metal ions, has been widely used for surface modification of materials since its discovery in the last decade. PDA and its derivatives can be used for the surface modification of orthopaedic implants to modulate cellular responses, including cell spreading, migration, proliferation, and differentiation, and may thereby enhance the function of existing implants. In addition, the osseointegration and antimicrobial properties of orthopaedic implants may also be improved by PDA-based coatings. The aim of this review is to provide a brief overview of current advances of surface modification technologies for orthopaedic implants using PDA and its derivatives as a medium. Given the versatility of PDA-based adhesion, such PDA-assisted surface modification technologies will certainly benefit the development of new orthopaedic implants. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: Surface treatments of orthopaedic implants, which are normally inert materials, are essential for their performance in vivo. This review summarizes recent advances in the surface modification of orthopaedic implants using facile and highly versatile techniques based on the use of polydopamine (PDA) and its derivatives.Entities:
Keywords: Implants; Orthopaedic; Polydopamine; Surface modification
Year: 2019 PMID: 31194087 PMCID: PMC6551362 DOI: 10.1016/j.jot.2019.04.001
Source DB: PubMed Journal: J Orthop Translat ISSN: 2214-031X Impact factor: 5.191
Figure 1(A) Photograph of blue mussel binding to Teflon and molecular structure of DOPA and dopamine [9]. (B) Location of adhesive-related proteins identified in the byssus of Mytilus edulis[9]. (C) A schematic illustration of thin film deposition of PDA by dip coating within an alkaline dopamine solution [8]. (D) Thickness evolution of PDA coating on Si as measured by atomic force microscopy (AFM) of patterned surfaces [8]. (E) X-ray photoelectron spectroscopy (XPS) characterization of 25 different PDA-coated surfaces [8]. Reprinted with permission from ref. [8], 2007, American Association for the Advancement of Science and ref. [9], 2011, Royal Society of Chemistry Publishing Group. HAp = hydroxyapatite; PS = polystyrene; PE = polyethylene; PC = polycarbonate; PET = polyethylene terephthalate; PTFE = polytetrafluoroethylene; PU = polyurethane; DOPA = 3,4-dihydroxy-l-phenylalanine; PDA = polydopamine; PDMS = polydimethylsiloxane; PEEK = poly(ether ether ketone).
Typical thickness and deposition rate of PDA coatings at different conditions.
| Condition | Time (h) | Thickness (nm) | Thickness/time (nm h−1) | References |
|---|---|---|---|---|
| Pure O2, pH 8.5 | 0.5 | 4.4 | 8.8 | |
| CuSO4/H2O2, pH 8.5 | 0.67 | 30 | 44.8 | |
| Sodium periodate, pH 5.0 | 2 | 100 | 50.0 | |
| UV, pH 8.5/pH 7.0 | 2 | 4.0 | 2.0 | |
| Ammonium persulfate, pH 7.0 | 2 | 70.0 | 35.0 | |
| Air, pH 8.5 | 24 | 50.0 | 2.1 | |
| CuSO4, pH 8.5 | 80 | 70 | 0.9 |
PDA = polydopamine.
Figure 2Overall view of three reaction pathways involved in polydopamine formation. Reprinted with permission from ref. [26], 2013, John Wiley and Sons Publishing Group.
Figure 3(A) Scheme for PDA-assisted calcium phosphate crystal formation. (B) The morphology of Ti and PDA-modified Ti substrate (Ti-PDA) after immersing in SBF for two days. (C) The entire surface of Ti-PDA was covered with calcium phosphate minerals and lath-like structures, typically found in natural HA crystals, after incubation for 14 days. Reprinted with permission from ref. [47], 2010, John Wiley and Sons Publishing Group. SBF = simulated body fluid; HA = hydroxyapatite; PDA = polydopamine.
Figure 4(A) Schematic illustration of (PDA/HA) composite coating self-assembly and characterization of the biological properties on the Ti surface [54]. (B) Poly(MeOEGMA) modified on the patterned areas and their resistance to cell adhesion [55]. Reprinted with permission from ref. [55], 2013, John Wiley and Sons Publishing Group. HA = hydroxyapatite; NP = nanoparticle; SD = Sprague-Dawley; ATRP = atom transfer radical polymerization; BMP-2 = bone morphogenic protein-2; PDA = polydopamine.
In vitro cell responses on implants modified by PDA-assisted methods.
| Substrates | Surface composition | Cell type | Adhesion | Proliferation | Osteogenic differentiation | References |
|---|---|---|---|---|---|---|
| PCLDA | PDA coating | hMSCs | √ | √ | ||
| Parafilm | PDA coating | ADMSCs | √ | √ | √ | |
| Calcium silicate/PCL | PDA coating | WJMSCs | √ | √ | ||
| Alginate | PDA coating and silver nanoparticles | BMSCs | √ | √ | ||
| PCL | PDA-coated/HA precipitate | hMSCs | √ | √ | √ | |
| op-HA/PLGA | Immobilized peptides by PDA | MC3T3-E1 | √ | √ | √ | |
| Porous SiO2 | PDA layer loading dexamethasone | BMSCs | √ | √ | √ | |
| β-TCP | PDA NPs | BMSCs | √ | √ | ||
| Ti | PDA/HA coatings | MG63 | √ | √ | √ | |
| Ti | PDA/BMP-2 coating | PDLSCs | √ | |||
| Ti | Microporous PDA architectures adsorbing BMP-2 | BMSCs | √ | √ | √ | |
| Ti | PDA/HA/BMP-2 composite coating | BMSCs | √ | √ | √ |
BMP-2 = bone morphogenic protein-2; PCLDA = poly(ε-caprolactone) diacrylate; PCL = polycaprolactone; HA = hydroxyapatite; β-TCP = β-tricalcium phosphate; NPs = nanoparticles; BMSCs = bone marrow mesenchymal stem cells; hMSCs = human mesenchymal stem cells; ADMSCs = adipose-derived mesenchymal stem cells; PDA = polydopamine; PDLSC = periodontal ligament stem cell; PLGA = poly(lactic-co-glycolic acid); WJMSC = Wharton's jelly mesenchymal stem cell.
In vivo bone regeneration of implants modified by PDA-assisted method.
| Materials | Surface composition | Animal model | Time | References |
|---|---|---|---|---|
| PLLA electrospun fibres | PDA coating | Mouse calvarial critical size defect | 8 weeks | |
| PLGA electrospun fibres | Immobilize BFP1 onto the surface by PDA coating | Mouse calvarial critical size defect | 8 weeks | |
| PLLA nanofibres | Immobilize BMP-2 onto the surface by PDA coating | Mouse calvarial critical size defect | 8 weeks | |
| Ti | BMP-2–loaded PDA/HA composite coating | Bone marrow cavity of SD rats | 12 weeks | |
| Ti | BMP–HA–PDA multilayer nanofilms | Medullary cavity of SD rats | 12 weeks | |
| Porous Ti6Al4V scaffolds | HA/PDA coating | Rabbit femoral condylar defects | 12 weeks | |
| Ti particles | Ti particle–induced calvarial osteolysis model in mice | 2 weeks |
PLLA = Poly(L-lactide); SD = Sprague-Dawley; BFP1 = bone-forming peptide 1; BMP-2 = bone morphogenic protein-2; PDA = polydopamine; PLGA = poly(lactic-co-glycolic acid).
Figure 5(A) MicroCT analysis of skull bones implanted with nanofibres at two months after surgery [70]. (B) Schematic drawing of the implant and its insertion site and histological sections of the implants stained with methylene blue and basic fuchsin 12 weeks after implantation [73]. (C) MicroCT images of the pTi and HA/PDA-pTi implants at 12 weeks and the yellow colour component was newly formed bone in these scaffolds [7]. Reprinted with permission from ref. [70], 2016, ref. [7] and ref. [72], 2014, ACS Publishing Group. CT = computed tomography; BMP = bone morphogenic protein; CB = cortical bone; NB = new bone; OC = osteocytes; PDA = polydopamine; S = sample.
Figure 6Surface modification of orthopaedic implants by PDA-assisted techniques. PDA = polydopamine.